Literature DB >> 24649056

Inhibition of ubiquitin protein expression and 20S proteasome activity by irbesartan prevents post-infarction ventricular remodeling and decreases TNF-α generation.

Naiju Zhang1, Tianping Chen2, Chunfang Liu2, Bi Tang2, Ling Nie3, Huiling An3, Duilan Zhao3, Li Pan3, Meiling Yu1.   

Abstract

Myocardial infarction (MI) may induce severe alterations of the cardiac contractile function that may, in turn, lead to heart failure (HF). The ubiquitin-proteasome system (UPS) plays a critical role in cardiac remodeling following MI. Angiotensin II type 1 receptor (AT1R) blockers effectively prevent left ventricular (LV) remodeling. However, it has not been elucidated whether the preventive effect of AT1R-blockers on LV remodeling is mediated through the UPS pathway. In the present study, with the use of cardiac morphometric parameters, haemodynamic measurements and enzyme-linked immunosorbent assay, we demonstrated that post-ischemic HF rats exhibited a significant increase in ventricular remodeling and irbesartan was effective in reversing cardiac remodeling. The expression of TNF-α, ubiquitin protein and 20S proteasome were significantly increased in the MI control group and irbesartan was shown to dose-dependently inhibit the expression of TNF-α, ubiquitin protein and 20S proteasome. In conclusion, it was hypothesized that UPS signaling is involved in ventricular remodeling following MI and the mechanism underlying the effect of irbesartan on ventricular remodeling may be associated with the downregulation of the expression of TNF-α, ubiquitin protein and 20S proteasome.

Entities:  

Keywords:  20S proteasome; heart failure; irbesartan; ubiquitine protein; ventricular remodeling

Year:  2013        PMID: 24649056      PMCID: PMC3917078          DOI: 10.3892/br.2013.165

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  29 in total

1.  Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.

Authors:  C Richer; M Gervais; P Fornes; J F Giudicelli
Journal:  J Cardiovasc Pharmacol       Date:  1999-12       Impact factor: 3.105

2.  Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction.

Authors:  M C Daniëls; R S Keller; P P de Tombe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-11       Impact factor: 4.733

3.  Proteasome inhibition in hypertrophied myocardium.

Authors:  Ingeborg Friehs
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-15       Impact factor: 4.733

4.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

5.  Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.

Authors:  C Richer; P Fornes; C Cazaubon; V Domergue; D Nisato; J F Giudicelli
Journal:  Cardiovasc Res       Date:  1999-01       Impact factor: 10.787

6.  The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control.

Authors:  Raffaele Marfella; Clara Di Filippo; Michele Portoghese; Mario Siniscalchi; Simone Martis; Franca Ferraraccio; Salvatore Guastafierro; Gianfranco Nicoletti; Michelangela Barbieri; Antonino Coppola; Francesco Rossi; Giuseppe Paolisso; Michele D'Amico
Journal:  Cardiovasc Pathol       Date:  2009-01-14       Impact factor: 2.185

Review 7.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

8.  Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.

Authors:  Hiroyuki Tsutsui; Shouji Matsushima; Shintaro Kinugawa; Tomomi Ide; Naoki Inoue; Yukihiro Ohta; Takashi Yokota; Sanae Hamaguchi; Kenji Sunagawa
Journal:  Hypertens Res       Date:  2007-05       Impact factor: 3.872

9.  Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.

Authors:  Eiichiro Yamamoto; Keiichiro Kataoka; Haruo Shintaku; Takuro Yamashita; Yoshiko Tokutomi; Yi-Fei Dong; Shinji Matsuba; Hidenori Ichijo; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-11       Impact factor: 8.311

10.  Long-term use and tolerability of irbesartan for control of hypertension.

Authors:  Valentina Forni; Grégoire Wuerzner; Menno Pruijm; Michel Burnier
Journal:  Integr Blood Press Control       Date:  2011-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.